Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34467574 | 1.00 | ACACB (0.44) | ACACBCYP11B2KITGPR119RET | |
| SCHEMBL10320047 | 0.90 | RET (0.47) | KITGPR119RETTSHR | |
| SCHEMBL25215747 | 0.84 | MEN1 (0.39) | CYP3A4CYP2D6TSHRCYP2C19HSD17B10 | |
| SCHEMBL2365638 | 0.81 | RET (0.47) | KITGPR119RETTSHR | |
| SCHEMBL2366029 | 0.79 | RET (0.46) | KITGPR119RETTSHR | |
| SCHEMBL2366027 | 0.79 | RET (0.46) | KITGPR119RETTSHR | |
| SCHEMBL22322349 | 0.78 | MEN1 (0.54) | KITGPR119TSHR | |
| SCHEMBL23086870 | 0.78 | GPR119 (0.51) | KITGPR119 | |
| SCHEMBL22322291 | 0.78 | TLR9 (0.49) | KITGPR119 | |
| SCHEMBL22322252 | 0.78 | CKS1B (0.46) | KITGPR119TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | ACACB 4757/4885CYP11B2 1449/4885KIT 2165/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | ACACB 4582/4885CYP11B2 690/4885KIT 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.